HAMBURG, Germany and ABINGDON, UK, Dec. 14, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has received a milestone payment from Ono Pharmaceutical Co., Ltd. (Ono) from its research collaboration aimed at identifying novel inhibitors for a protease target. The milestone is received for the progression of the medicinal chemistry collaboration into lead optimisation. The programme success validates again the strength of Evotec’s Fragment Based Drug Discovery platform, EVOlution(TM), along with its integrated drug discovery capabilities, including biology, medicinal chemistry, structure based drug design and in vitro pharmacology.
